Redoute-Timonnier Chloe, Auguste Patrick
University of Bordeaux, INSERM, BRIC, U1312, MIRCADE Team, F-33000 Bordeaux, France.
Cancers (Basel). 2024 Dec 5;16(23):4076. doi: 10.3390/cancers16234076.
Metastasis is the main cause of cancer-related deaths. The formation and growth of metastasis is a multistep process. Tumor cells extravasating in the secondary organ are in contact with a new microenvironment and a new extracellular matrix (ECM), called the metastatic niche. Some components of the ECM, such as periostin, can induce tumor cell growth in macrometastasis. In contrast, other components, such as Thrombospondin 1 (TSP-1), can maintain isolated cells in a dormant state. During dormancy, intracellular signaling activation, such as p38, maintains tumor cells arrested in the cell-cycle G0 phase for years. At any moment, stress can induce ECM modifications and binding to their specific receptors (mainly integrins) and reactivate dormant tumor cell growth in macrometastasis. In this review, we describe the tumor microenvironment of the different niches implicated in tumor cell dormancy. The role of ECM components and their associated receptors and intracellular signaling in the reactivation of dormant tumor cells in macrometastasis will be emphasized. We also present the different methodologies and experimental approaches used to study tumor cell dormancy. Finally, we discuss the current and future treatment strategies to avoid late metastasis relapse in patients.
转移是癌症相关死亡的主要原因。转移的形成和发展是一个多步骤过程。在继发器官中渗出的肿瘤细胞与一种新的微环境和一种新的细胞外基质(ECM)接触,这种微环境和细胞外基质被称为转移龛。ECM的一些成分,如骨膜蛋白,可在大转移中诱导肿瘤细胞生长。相反,其他成分,如血小板反应蛋白1(TSP-1),可使孤立的细胞保持休眠状态。在休眠期间,细胞内信号激活,如p38,可使肿瘤细胞在细胞周期的G0期停滞数年。在任何时候,应激都可诱导ECM修饰并与其特异性受体(主要是整合素)结合,从而重新激活大转移中休眠肿瘤细胞的生长。在这篇综述中,我们描述了与肿瘤细胞休眠相关的不同龛的肿瘤微环境。将重点强调ECM成分及其相关受体和细胞内信号在大转移中休眠肿瘤细胞重新激活中的作用。我们还介绍了用于研究肿瘤细胞休眠的不同方法和实验途径。最后,我们讨论了避免患者晚期转移复发的当前和未来治疗策略。
Cancers (Basel). 2024-12-5
Cancer Metastasis Rev. 2023-3
Cancers (Basel). 2021-9-30
Eur J Cancer. 2010-3-19
J Biol Eng. 2018-12-27
Cancer Lett. 2024-6-1
Adv Cancer Res. 2019-1-16
Cancer Cell Int. 2024-7-20
Cancer Metastasis Rev. 2024-12
J Bone Oncol. 2024-3-21